---
title: "🐳 The 3 stocks with the most noteworthy unusual option block trades! What are they betting on?"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39445949.md"
description: "①$Karyopharm Therap(KPTI.US) — Call option volume reached 13,511 contracts, 11 times the daily average. The main force bought 6,700 times (totaling 13,400 contracts) on the 10/17.50 call spread expiring on April 17th. Since the current open interest is only 2,800 contracts, it can be confirmed as entirely new positions, with a clear bullish direction. HC Wainwright maintains a Buy rating with a target price of $15. The market may be betting on XPOVIO's new indication data or M&A news..."
datetime: "2026-03-23T10:21:58.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39445949.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39445949.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39445949.md)
author: "[Alpha-Flow](https://longbridge.com/en/profiles/26895775.md)"
---

# 🐳 The 3 stocks with the most noteworthy unusual option block trades! What are they betting on?

**①**$Karyopharm Therap(KPTI.US) **— Bullish**

Option volume reached 13,511 contracts, 11 times the daily average. The main force bought 6,700 times (13,400 contracts in total) on the April 17th expiry 10/17.50 bullish call spread. Since the current open interest is only 2,800 contracts, this can be confirmed as entirely new positions, clearly indicating a bullish direction. HC Wainwright maintains a Buy rating with a target price of $15. The market may be betting on new XPOVIO indication data or M&A news.

**②** $Revolution Medicines(RVMD.US) **— Neutral to Bullish (Sell Put Spread)**

RVMD's put option volume exceeded 10,335 contracts, 65 times the average daily put volume. The main force sold 5,000 contracts of the 90/70 put vertical spread, collecting a premium of $6.25 per contract, indicating institutions believe the stock price will not fall below $90. Previous acquisition talks (with Merck) broke down due to price disagreements, but analysts remain optimistic about its RAS-targeted pipeline and dense 2026 milestone schedule. The company expects to disclose key Phase III RASolute 302 data for daraxonrasib in pancreatic cancer in the first half of this year.  

**③** $Exxon Mobil(XOM.US) **— Super Aggressively Bullish**

A single $12 million bullish block trade appeared after-hours, executed at the Ask price, with a volume/open interest ratio as high as 4,562 times. The strike price even exceeded the market's implied volatility cap. The background is a Wall Street Journal report that US fighter jets and helicopters have begun operations to reopen the Strait of Hormuz, sharply increasing geopolitical oil price risks.

⚠️ **Risk Warning**: Unusual option activity only reflects market activity, does not represent insider information, and does not constitute any investment advice. Option trading carries extremely high risks; please evaluate carefully.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [XOM.US](https://longbridge.com/en/quote/XOM.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)